These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32628648)

  • 1. Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
    Zhang T; George DJ
    Clin Adv Hematol Oncol; 2020 Apr; 18(4):204-207. PubMed ID: 32628648
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
    Shamash J; Powles T; Wilson P; Ansell W; Oliver T
    J Clin Oncol; 2005 Feb; 23(6):1323-5. PubMed ID: 15718335
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331
    [No Abstract]   [Full Text] [Related]  

  • 4. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
    Gunjur A
    Lancet Oncol; 2018 May; 19(5):e232. PubMed ID: 29606588
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
    Rini BI
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):115-117. PubMed ID: 29741511
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 8. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 9. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of UFT in far-advanced renal cell carcinoma].
    Matsuyama H; Yamamoto N; Sakatoku J; Hara Y; Sacho T; Yasui H; Ichikawa T; Koshido Y; Hayasida S; Nagata K
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):527-30. PubMed ID: 3126711
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting survival of patients with metastatic renal cell carcinoma.
    Motzer RJ; Mazumdar M
    Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and everolimus in renal cancer: a rational way forward.
    Stadler WM; Phillips G; George DJ; Halabi S; Small E
    J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
    Yagoda A; Abi-Rached B; Petrylak D
    Semin Oncol; 1995 Feb; 22(1):42-60. PubMed ID: 7855619
    [No Abstract]   [Full Text] [Related]  

  • 15. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 16. Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Mashiach T; Native O; Stein A; Kuten A
    J Chemother; 2007 Feb; 19(1):79-84. PubMed ID: 17309855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.
    Bergerat JP; Herbrecht R; Dufour P; Jacqmin D; Bollack C; Prevot G; Bailly G; de Garis S; Juraschek F; Oberling F
    Cancer; 1988 Dec; 62(11):2320-4. PubMed ID: 3141036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapeutic strategies for renal cell carcinoma.
    Milowsky MI; Nanus DM
    Urol Clin North Am; 2003 Aug; 30(3):601-9, x. PubMed ID: 12953758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.